---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-094701"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2024-04-12T23:59:59+00:00"
generated_at: "2026-06-03T23:16:40.957631+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vaccinex receives Nasdaq notice for failing minimum equity requirement

## Summary
- Nasdaq notice on April 11, 2024: Vaccinex lacks $2.5M minimum stockholders' equity for continued listing.
- Company also fails alternative standards: market value of listed securities $35M or net income $500k.
- Deadline to submit compliance plan is May 13, 2024; Nasdaq may grant extension if plan accepted.
- No immediate delisting, but failure to regain compliance could lead to delisting of VCNX common stock.
- Management evaluating options but cannot assure regaining or maintaining compliance.

## SEC filing metadata
- accession: 0001193125-24-094701
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2024-04-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312524094701/0001193125-24-094701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312524094701/d719945d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-094701
- JSON: https://secwatch.observer/filing/0001193125-24-094701.json
- Plain text: https://secwatch.observer/filing/0001193125-24-094701.txt

## Key facts
- Listing & Compliance Notices
  VACCINEX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: April 11, 2024, Vaccinex, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the financial statements contained in its Form 10-K for the year-ended December 31, 2023, the Company no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”) or the alternative requirements of having a market value of listed securities of $35 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1205922/000119312524094701/0001193125-24-094701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.